During 2018 Q3 the big money sentiment increased to 0.93. That’s change of 0.24, from 2018Q2’s 0.69. 19 investors sold all, 21 reduced holdings as Achaogen, Inc. ratio improved. 20 grew stakes while 17 funds amassed stakes. Funds hold 17.23 million shares thus 23.75% less from 2018Q2’s 22.60 million shares.
Dekabank Deutsche Girozentrale owns 16,500 shs or 0% of their US capital. Point72 Asset Limited Partnership stated it has 0% in Achaogen, Inc. (NASDAQ:AKAO). Edge Wealth Mgmt Lc stated it has 0% in Achaogen, Inc. (NASDAQ:AKAO). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in Achaogen, Inc. (NASDAQ:AKAO). Grp One Trading L P reported 162,252 shs. Alliancebernstein Ltd Partnership accumulated 60,700 shs. Parallax Volatility Advisers Lp reported 4,398 shs stake. Gamco Et Al has 0% invested in Achaogen, Inc. (NASDAQ:AKAO) for 174,400 shs. Citigroup has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Ameritas Inv Prtn has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Ubs Asset Management Americas reported 30,496 shs. Schwab Charles Investment Mngmt stated it has 147,306 shs. Teton Advisors has invested 0.09% in Achaogen, Inc. (NASDAQ:AKAO). Blair William And Il has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Ny State Common Retirement Fund holds 0% in Achaogen, Inc. (NASDAQ:AKAO) or 42,050 shs.

Achaogen, Inc. registered $1.95 million net activity with 5 buys and 3 sales since September 25, 2018. 157,760 Achaogen, Inc. (NASDAQ:AKAO) shs with value of $281,606 were bought by DUGGAN ROBERT W. Wise Blake sold 3,242 shs worth $13,454. 1,038 shs valued at $4,308 were sold by LOEB GARY on Tuesday, September 25.

By reaching $0.77 share price all time low was [achieved] by Achaogen, Inc. (NASDAQ:AKAO). The all time low was posted by Barchart.com. It has $48.89M MC. At $0.73 stock price target, the company valuation changes by $2.93 million less.

The stock increased 6.67% or $0.0484 during the last trading session, hitting $0.7735.Achaogen, Inc. has 1.92M shares volume, 36.81% up from normal. AKAO is downtrending and has moved 83.95% since March 2, 2018. AKAO underperformed by 83.95% the S&P 500.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Total analysts of 6 have positions in Achaogen (NASDAQ:AKAO) as follows: 0 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 0. Since November 9, 2018 according to StockzIntelligence Inc Achaogen has 7 analyst reports. On Thursday, February 21 H.C. Wainwright maintained Achaogen, Inc. (NASDAQ:AKAO) rating. H.C. Wainwright has “Hold” rating and $2 target. In Monday, November 12 report H.C. Wainwright downgraded the stock to “Neutral” rating. On Friday, November 9 the firm has “Hold” rating by Stifel Nicolaus given. On Monday, November 12 the firm earned “Neutral” rating by Wedbush. On Friday, November 9 the stock of Achaogen, Inc. (NASDAQ:AKAO) has “Neutral” rating given by Mizuho. The stock rating was downgraded by SunTrust to “Hold” on Tuesday, November 13. On Friday, November 9 the rating was downgraded by Cowen & Co to “Market Perform”.

For more Achaogen, Inc. (NASDAQ:AKAO) news released recently go to: Nasdaq.com, Benzinga.com, Nasdaq.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Health Care Sector Update for 02/15/2019: AKAO, ORPN, CGC, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” released on February 15, 2019, “Daily Biotech Pulse: Genomic Health Earnings, AbbVie’s Humira Approved For Another Indication In Japan – Benzinga” on February 21, 2019, “Health Care Sector Update for 02/15/2019: BSX,LLY,LOXO,ORPN,AKAO – Nasdaq” with a publish date: February 15, 2019, “Achaogen Announces Pricing of $15 Million Underwritten Public Offering – GlobeNewswire” and the last “Conformis and Avadel Pharmaceuticals among healthcare gainers; Achaogen leads the losers – Seeking Alpha” with publication date: February 15, 2019.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States.The company has $48.89 million market cap. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae.Currently it has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.